Literature DB >> 12770935

Mechanism of kinin release during experimental acute pancreatitis in rats: evidence for pro- as well as anti-inflammatory roles of oedema formation.

Thomas Griesbacher1, Irmgard Rainer, Beate Tiran, Edwin Fink, Fred Lembeck, Bernhard A Peskar.   

Abstract

1 Kinin B(2) receptor antagonists or tissue kallikrein (t-KK) inhibitors prevent oedema formation and associated sequelae in caerulein-induced pancreatitis in the rat. We have now further investigated the mechanism of kinin generation in the pancreas. 2 Kinins were elevated in the pancreatic tissue already before oedema formation became manifest. Peak values (421+/-59 pmol g(-1) dry wt) were reached at 45 min and remained elevated for at least 2 h; a second increase was observed at 24 h. Pretreatment with the B(2) receptor antagonist icatibant abolished kinin formation, while post-treatment was ineffective. 3 Total kininogen levels were very low in the pancreas of controls, but increased 75-fold during acute pancreatitis. This increase was absent in rats that were pretreated with icatibant. 4 During pancreatitis, t-KK-like and plasma kallikrein (p-KK)-like activity in the pancreas, as well as trypsinogen activation peptide (TAP) increased significantly. Icatibant pretreatment further augmented t-KK about 100-fold, while p-KK was significantly attenuated; TAP levels remained unaffected. 5 Endogenous protease inhibitors (alpha(1)-antitrypsin, alpha(2)-macroglobulin) were low in normal tissues, but increased 45- and four-fold, respectively, during pancreatitis. This increase was abolished when oedema formation was prevented by icatibant. 6 In summary, oedema formation is initiated by t-KK; the ensuing plasma protein extravasation supplies further kininogen and active p-KK to the tissue. Concomitantly, endogenous protease inhibitors in the oedema fluid inhibit up to 99% of active t-KK. Our data thus suggest a complex interaction between kinin action and kinin generation involving positive and negative feedback actions of the inflammatory oedema.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12770935      PMCID: PMC1573846          DOI: 10.1038/sj.bjp.0705247

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  43 in total

1.  Human bradykinin B(2) receptor is activated by kallikrein and other serine proteases.

Authors:  C Hecquet; F Tan; B M Marcic; E G Erdös
Journal:  Mol Pharmacol       Date:  2000-10       Impact factor: 4.436

2.  Involvement of tissue kallikrein but not plasma kallikrein in the development of symptoms mediated by endogenous kinins in acute pancreatitis in rats.

Authors:  Thomas Griesbacher; Irmgard Rainer; Beate Tiran; D Michael Evans
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

Review 3.  Bradykinin and inflammatory pain.

Authors:  A Dray; M Perkins
Journal:  Trends Neurosci       Date:  1993-03       Impact factor: 13.837

4.  Identification of rat urinary kinin as bradykinin.

Authors:  Y Hagiwara; M Kojima; T Kuraishi; I Hayashi; T Miyata; S Oh-ishi
Journal:  Life Sci       Date:  1995       Impact factor: 5.037

5.  The myostimulating effect of tissue kallikrein on rat uterus.

Authors:  J Damas; V Bourdon; J C Pinto
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-05       Impact factor: 3.000

6.  Activation of trypsinogen in experimental models of acute pancreatitis in rats.

Authors:  Y Nakae; S Naruse; M Kitagawa; S Hirao; R Yamamoto; T Hayakawa
Journal:  Pancreas       Date:  1995-04       Impact factor: 3.327

Review 7.  Receptors for bradykinin and related kinins: a critical analysis.

Authors:  D Regoli; D Jukic; F Gobeil; N E Rhaleb
Journal:  Can J Physiol Pharmacol       Date:  1993-08       Impact factor: 2.273

Review 8.  Experimental animal models of acute pancreatitis.

Authors:  M M Lerch; G Adler
Journal:  Int J Pancreatol       Date:  1994-06

9.  Pathological events in experimental acute pancreatitis prevented by the bradykinin antagonist, Hoe 140.

Authors:  T Griesbacher; B Tiran; F Lembeck
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

10.  Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies.

Authors:  K Wirth; F J Hock; U Albus; W Linz; H G Alpermann; H Anagnostopoulos; S Henk; G Breipohl; W König; J Knolle
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

View more
  4 in total

1.  Attenuation of persistent experimental pancreatitis pain by a bradykinin b2 receptor antagonist.

Authors:  Qingmin Chen; Louis P Vera-Portocarrero; Michael H Ossipov; Marina Vardanyan; Josephine Lai; Frank Porreca
Journal:  Pancreas       Date:  2010-11       Impact factor: 3.327

2.  Kallikrein inhibitors limit kinin B(2) antagonist-induced progression of oedematous to haemorrhagic pancreatitis in rats.

Authors:  T Griesbacher; I Rainer; B Tiran; B A Peskar
Journal:  Br J Pharmacol       Date:  2008-08-11       Impact factor: 8.739

3.  Calcium signalling in the acinar environment of the exocrine pancreas: physiology and pathophysiology.

Authors:  Oleksiy Gryshchenko; Julia V Gerasimenko; Shuang Peng; Oleg V Gerasimenko; Ole H Petersen
Journal:  J Physiol       Date:  2018-03-26       Impact factor: 5.182

4.  Activation of pancreatic stellate cells attenuates intracellular Ca2+ signals due to downregulation of TRPA1 and protects against cell death induced by alcohol metabolites.

Authors:  Agnieszka A Kusiak; Monika A Jakubowska; Kinga B Stopa; Xiaoying Zhang; Wei Huang; Julia V Gerasimenko; Oleg V Gerasimenko; Robert Sutton; Ole H Petersen; Pawel E Ferdek
Journal:  Cell Death Dis       Date:  2022-08-29       Impact factor: 9.685

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.